- Abbott Laboratories
- ACON Laboratories
- BD (Becton, Dickinson and Company)
- Beckman Coulter
- BioMérieux
- Cepheid
- Danaher Corporation
- Hologic
- LumiraDx
- QIAGEN
- Roche Diagnostics
- Siemens Healthineers
- Sysmex Corporation
- Thermo Fisher Scientific
- Vericel Corporation
1. Rising Incidence of Sepsis:
The growing global incidence of sepsis is a primary driver for the sepsis diagnostics market. Increasing awareness and improved healthcare reporting have led to more sepsis cases being diagnosed, especially in aging populations and immunocompromised individuals. Hospitals are focusing on early diagnosis to reduce morbidity and mortality, spurring demand for rapid and accurate diagnostic tools.
2. Advancements in Molecular Diagnostics:
Technological progress in molecular diagnostics, particularly PCR and biomarkers like procalcitonin, has significantly enhanced the speed and precision of sepsis identification. These innovations support timely interventions, reduce the misuse of antibiotics, and align with antimicrobial stewardship goals. Companies are investing in R&D to launch point-of-care systems, further influencing market growth.